Arnab Basu, MD

Articles

The Future of Advanced Renal Cell Carcinoma Management

May 4th 2022

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Using Cabozantinib + Nivolumab to Treat Advanced Renal Cell Carcinoma

May 4th 2022

A discussion on the use of cabozantinib-nivolumab for the treatment of advanced renal cell carcinoma.

Patient Profile Presentation: A 72-Year-Old Man Presenting with Hematuria

May 4th 2022

Dr Shawnta Anakwah presents the patient profile of a 72-year-old man with advanced renal cell carcinoma presenting with hematuria.

Adverse Events in IO-IO Combination Treatment Regimens for Advanced RCC

May 2nd 2022

Key opinion leaders discuss the common adverse events seen with IO/IO combination regimens and how to treat patients with brain metastases.

Approved First-Line IO-IO Combination Treatment Regimens for Advanced RCC

May 2nd 2022

A review of the first-line IO/IO combination regimens available for advanced RCC.

Patient Profile Presentation: A 48-Year-Old Man Presenting with a Right Renal Mass

April 19th 2022

Shawnta Anakwah, MD, presents the patient profile of a 48-year-old man with advanced renal cell carcinoma presenting with a right renal mass.

Duration of Treatment with IO-TKI Regimens and Treatment Options at Progression

April 19th 2022

Drs Anakwah and Basu share their thoughts on the duration of treatment with I/O–TKI regimens and what treatment options are available for patients at progression of renal cell carcinoma.

Adverse Events with IO-TKI Combination Regimens for Advanced RCC and Their Management

April 19th 2022

Experts review adverse events commonly observed with IO/TKI combination regimens in patients with RCC and how these are managed in clinical practice.

Selecting RCC Patients with Lenvatinib + Pembrolizumab Therapy and Appropriate Dosing Strategies

April 19th 2022

Oncologists discuss which patients with advanced RCC might be most suitable for treatment with lenvatinib + pembrolizumab and the appropriate dosing strategies for this regimen.

First-Line IO-TKI Combination Treatment Regimens for Advanced RCC

April 5th 2022

A review of the first-line IO/TKI combination regimens available for advanced RCC and the factors considered in choosing an appropriate treatment.

Patient Profile Presentation: A 58-Year-Old Woman Presenting with Gross Hematuria

April 5th 2022

Arnab Basu, MD, presents the patient profile of a 58-year-old woman with advanced renal cell carcinoma presenting with gross hematuria.